John Crowley, Amicus CEO (via YouTube)
January 11, 2022 06:49 AM ESTUpdated 07:00 AM
Bioregnum
Cell/Gene Tx

Am­i­cus gets hit with an 'un­ex­pect­ed' set­back on a gene ther­a­py tapped to lead $600M SPAC spin­out

Am­i­cus has tak­en the axe and chopped a gene ther­a­py for Bat­ten dis­ease out of the pipeline af­ter an “un­ex­pect­ed” set­back in the clin­ic. …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times